These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38999940)

  • 1. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
    Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
    Shen KY; Zhu Y; Xie SZ; Qin LX
    J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
    Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L
    Elife; 2024 Aug; 13():. PubMed ID: 39146202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status and future of targeted-immune combination for hepatocellular carcinoma.
    Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X
    Front Immunol; 2024; 15():1418965. PubMed ID: 39161764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.
    Li Y; Li F; Xu L; Shi X; Xue H; Liu J; Bai S; Wu Y; Yang Z; Xue F; Xia Y; Dong H; Shen F; Wang K
    Theranostics; 2024; 14(9):3526-3547. PubMed ID: 38948071
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.
    Iñarrairaegui M; Melero I; Sangro B
    Clin Cancer Res; 2018 Apr; 24(7):1518-1524. PubMed ID: 29138342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
    Roth GS; Decaens T
    Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.